Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB.

N Engl J Med. 2002 Mar 14;346(11):822-9.

2.

How companies stall generics and keep themselves healthy.

Stolberg SG, Gerth J.

N Y Times Web. 2000 Jul 23:A1, A14, A15. No abstract available.

PMID:
11785519
3.

Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect.

McAlister FA, Laupacis A, Wells GA, Sackett DL.

JAMA. 1999 Oct 13;282(14):1371-7. No abstract available.

PMID:
10527185
4.

The importance of the physician in the generic versus trade-name prescription decision.

Hellerstein JK.

Rand J Econ. 1998 Spring;29(1):108-36.

PMID:
10182437
5.

Generic substitution and optimal patient care.

Murphy JE.

Arch Intern Med. 1999 Mar 8;159(5):429-33. No abstract available.

PMID:
10074950
6.

Reflections on generic warfarin.

Haines ST.

Am J Health Syst Pharm. 1998 Apr 1;55(7):729-33. No abstract available.

PMID:
9558427
7.

In favor of Coumadin over generic warfarin.

Benson SR, Vance-Bryan K.

Am J Health Syst Pharm. 1998 Apr 1;55(7):727-9. No abstract available.

PMID:
9558426
8.

Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

DeCara JM, Croze S, Falk RH.

Chest. 1998 Feb;113(2):261-3. No abstract available.

PMID:
9498932
9.

From the Food and Drug Administration.

Nightingale SL.

JAMA. 1998 Mar 4;279(9):645. No abstract available.

PMID:
9496968
10.

A physician survey on generic drugs and substitution of critical dose medications.

Banahan BF 3rd, Kolassa EM.

Arch Intern Med. 1997 Oct 13;157(18):2080-8.

PMID:
9382664
11.

Generic warfarin: implications for patient care.

Wittkowsky AK.

Pharmacotherapy. 1997 Jul-Aug;17(4):640-3. No abstract available.

PMID:
9250543
12.

Drug patent expirations and the speed of generic entry.

Bae JP.

Health Serv Res. 1997 Apr;32(1):87-101.

13.

Thyroid storm.

Rennie D.

JAMA. 1997 Apr 16;277(15):1238-43. No abstract available.

PMID:
9103350
14.

Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.

Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS.

JAMA. 1997 Apr 16;277(15):1205-13.

PMID:
9103344
15.
16.

Bioequivalence of a generic slow-release theophylline tablet in children.

Kanthawatana S, Ahrens RC, McCubbin M, Bronsky E, Blake K, Hendeles L.

J Pediatr. 1994 Dec;125(6 Pt 1):987-91.

PMID:
7996375
17.

Therapeutic equivalence of a generic slow-release theophylline tablet.

Hendeles L, Breton AL, Beaty R, Harman E.

Pharmacotherapy. 1995 Jan-Feb;15(1):26-35.

PMID:
7739942
18.

Variation in biologic availability of digoxin from four preparations.

Lindenbaum J, Mellow MH, Blackstone MO, Butler VP Jr.

N Engl J Med. 1971 Dec 9;285(24):1344-7. No abstract available.

PMID:
5121186
19.

Non-equivalence of digoxin tablets.

Reissell P, Manninen V, Ojala K, Karjalainen J.

Ann Clin Res. 1974;6(0):suppl 11:4-8. No abstract available.

PMID:
4853359
20.

Bioavailability of digoxin.

Jounela AJ, Sothmann A.

Lancet. 1973 Jan 27;1(7796):202-3. No abstract available.

PMID:
4118816

Supplemental Content

Support Center